Novartis Reports Strong Q1 Results and Raises Full-Year Guidance

Tuesday, 23 April 2024, 22:25

Novartis (NYSE: NVS) exceeded analyst expectations with an 11% increase in net sales and a 14% rise in core net income in the first quarter. The company's strategic shift towards innovative medicines business and raised guidance for 2024 indicate confidence in future growth potential.
https://store.livarava.com/e5f3f227-01c0-11ef-a6bf-63e1980711b2.jpg
Novartis Reports Strong Q1 Results and Raises Full-Year Guidance

Double beats in the first quarter

A double beat on net sales and core net income in the first quarter boosted Novartis stock by over 2%. CEO Vas Narasimhan highlighted the company's performance across growth brands and geographies.

Guidance raised, although still not very specific

Novartis raised its full-year 2024 guidance with expectations of high-single-digit to low-double-digit growth in net sales. However, the company did not provide guidance for net income figures, signaling cautious optimism for the future.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Get the most reliable and up-to-date financial news with our curated selections. Subscribe to our newsletter for convenient access and enhance your analytical work effortlessly.

Subscribe